All In Biotech

Drug Trial Radar · NCT02345226

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects

Last checked: Nov 20, 2026Latest source record: Jan 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 881 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

881

Actual

Start

Jan 26, 2015

Primary completion

Jun 29, 2016

Study completion Jan 2, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jan 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen of efavirenz /FTC/tenofovir disoproxil fumarate (EFV/FTC/TDF) FDC in virologically-suppressed HIV-1 infected participants.

Conditions

  • HIV-1 Infection

Interventions

  • FTC/RPV/TAFDrug

    200/25/25 mg FDC tablets administered orally once daily

  • EFV/FTC/TDF PlaceboDrug

    Tablets administered orally once daily

  • EFV/FTC/TDFDrug

    600/200/300 mg FDC tablets administered orally once daily

  • FTC/RPV/TAF PlaceboDrug

    Tablets administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48

Locations

117 sites in 9 countries. Site status is shown where the registry gives one.

  • Maricopa Integrated Health System

    Phoenix, Arizona

  • Spectrum Medical Group

    Phoenix, Arizona

  • AHF Research Center

    Beverly Hills, California

  • Pacific Oaks Medical Group

    Beverly Hills, California

  • Long Beach Education and Research Consultants

    Long Beach, California

  • Kaiser Permanente

    Los Angeles, California

  • Southern California Men's Medical Group

    Los Angeles, California

  • Tarrant County ID Associates

    Los Angeles, California

  • Kaiser Permanente

    Sacramento, California

  • University of California-UC Davis

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • Kaiser Permanente

    San Francisco, California

  • Optimus Medical

    San Francisco, California

  • Kaiser Permanente

    San Leandro, California

  • Los Angeles BioMedical Institute at Harbor-UCLA Medical Center

    Torrance, California

  • University of Colorado

    Aurora, Colorado

  • Apex Research Institute

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • World Health Clinicians' CIRCLE CARE Center

    Norwalk, Connecticut

  • Capital Medical Associates, P.C.

    Washington D.C., District of Columbia

  • Medical Faculty Associates, Inc.

    Washington D.C., District of Columbia

  • Whitman Walker Clinic

    Washington D.C., District of Columbia

  • Gary Richmond, MD, PA, Inc.

    Fort Lauderdale, Florida

  • Therafirst Medical Centers

    Fort Lauderdale, Florida

  • Midway Immunology & Research Center, LLC

    Ft. Pierce, Florida

  • AIDS Healthcare Foundation

    Miami, Florida

  • University of Miami

    Miami, Florida

  • AIDS Healthcare Foundation

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Infectious Diseases Associates of NW Florida, P.A.

    Pensacola, Florida

  • Hillsborough County Health Dept.

    Tampa, Florida

  • Infectious Disease Research Institute Inc.

    Tampa, Florida

  • St. Joseph's Comprehensive Research Institute

    Tampa, Florida

  • AIDS Research & Treatment Center of the Treasure Coast

    Vero Beach, Florida

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida

  • Rowan Tree Medical PA

    Wilton Manors, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • Atlanta ID Group

    Atlanta, Georgia

  • Infectious Disease Specialists of Atlanta

    Decatur, Georgia

  • Mercer University School of Medicine

    Macon, Georgia

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.